All results

26 results for randomized double blind multiple dose placebo controlled study evaluate safety

• Armata

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All

• diSArm

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All

• A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Underg

  An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155…

  Ages

  18 Years - N/A

  Sexes

  All

• ATYR

  This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…

  Ages

  18 Years - 75 Years

  Sexes

  All

• CTD-TCNPC-301

  A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann…

  Ages

  3 Years - N/A

  Sexes

  All

• JNT-517

  The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD)…

  Ages

  18 Years - 65 Years

  Sexes

  All

• Edgewise-210

  The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…

  Ages

  4 Years - 9 Years

  Sexes

  Male

• EMBARK

  The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The…

  Ages

  4 Years - 7 Years

  Sexes

  Male

• A1334-02

  The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants…

  Ages

  18 Years - N/A

  Sexes

  All

• PROTECT Extension Study

  The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in…

  Ages

  9 Years - 19 Years

  Sexes

  All